David Thorpe, John Clouston, and Leonard Keenan have joined Ariadne’s North American and European sales teams, Ariadne Genomics said this week.
Clouston joins Ariadne as sales manager in the North American market. Previously, he held a similar position at Silicon Genetics (now GeneSpring at Agilent Technologies).
Thorpe has been appointed director of enterprise sales and will lead corporate and enterprise sales efforts in North America and Europe. He held senior-level positions at OriGene Technologies, CambridgeSoft, and InforMax (now Invitrogen).
Keenan serves as business development associate for the European market. He previously held business development and sales management positions at a variety of software companies.
The Massachusetts Institute of Technology’s Robert Langer has joined the Accelrys NanoBiology Initiative's scientific advisory committee.
Langer is the institute professor in chemical and biomedical engineering.
Langer joins initiative chair Leroy Hood, president of the Institute for Systems Biology, as the second member of the committee.
Exagen Diagnostics added three director-level positions with John Adair, John Burns, and Petra Schwartz.
Adair is the director of quality and Schwartz is the director of human resources. They will be based in the company's Albuquerque, NM, office.
As the lead software architect, Burns will be based in Houston, Texas.
Adair specialized in the pharmaceutical, medical device, biopharmaceutical, and in vitro diagnostic manufacturing industries. Most recently, Adair was vice president of worldwide quality at Immucor and held quality-related positions at BioPort, ROCAP, Schein Pharmaceutical, Abbott Laboratories, and Becton Dickinson.
John Abeles joined CombiMatrix’s Scientific Advisory Board, Acacia Research today.
Abeles practiced medicine in London before becoming a senior executive in Pfizer, Sterling Drug, and Revlon Health Care. He was a healthcare analyst with Kidder Peabody and later formed MedVest, a healthcare consulting firm.
Abeles received his medical degree as well as a degree in pharmacology from the University of Birmingham, UK.
Additionally, CombiMatrix has hired Shelly Gunn as a medical director for its CombiMatrix Molecular Diagnostics unit.
Gunn earned her BA and Master's degrees from Trinity University. She received her MD and PhD degrees from the University of Texas Health Science Center at San Antonio Graduate School of Biomedical Sciences.